+44 (0)1865 595230
0 Items

Corynebacterium diphtheriae

Diphtheria is a serious bacterial infection of the respiratory tract. It remains a problem in parts of the world where vaccine coverage is low.

Diphtheria can cause serious inflammation of the throat. The bacteria release a toxin that leads to the formation of a thick greyish-white membrane over the back of the throat and in the most severe cases block the airway. Infection can be fatal.

At The Native Antigen Company we offer both purified and activity tested diphtheria toxin itself and antibodies specific for the toxin, to support IVD assay development and vaccine R&D and also

Corynebacterium diphtheriae background

The gram-positive bacillus Corynebacterium diphtheriae was first identified in 1888 as the causative agent for the infectious disease known as diphtheria. The bacterium is spread from person-to-person through infected aerosols distributed by coughing or sneezing, and through contact with surfaces contaminated with infected secretions.

The disease caused by C. diphtheriae primarily affects the throat and upper respiratory tract, but the toxin can affect other organs. The symptoms of the disease are sore throat, malaise, low-grade fever and swollen neck glands. The toxin can also cause a membrane of dead cells to form over the throat and tonsils resulting in breathing difficulties, and in some cases death from asphyxia. In severe cases, the toxin may cause neurological complications or heart failure. Patients with diphtheria are currently treated with antibiotics to kill the bacteria, and antitoxin to neutralise the effects of the diphtheria toxin (CDC).

Since 1945, diphtheria vaccines and vaccination programs have been successful in reducing cases of diphtheria worldwide by 99%. However, diphtheria is still a significant problem in some countries and outbreaks have been reported in the former Soviet Union, India, Myanmar, Malaysia and the Philippines, which may be due to poor immunisation programs or poor vaccine quality. In addition, waning immunity to diphtheria toxin may occur in individuals who have been immunised in childhood but have not been exposed to diphtheria in later life. Various global studies report that diphtheria seronegativity increases with age, suggesting that booster vaccinations may be necessary in adults (WHO, 2017).

References

  1. Freeman VJ, Morse IU. (1952). Further observations on the change to virulence of bacteriophage-infected a virulent strains of Corynebacterium diphtheria. J Bacteriol. Mar;63(3):407-14.
  2. Center for Disease Control and Prevention: Diphtheria
  3. World health Organization: Diphtheria vaccine. Review of evidence on vaccine effectiveness and immunogenicity to assess the duration of protection ≥10 years after the last booster dose. April 2017
  4. Center for Disease Control and Prevention: Diphtheria, prevention

Corynebacterium diphtheriae Antigens

Diphtheria toxin (DT) is a 62 kDa protein that belongs to the family of ADP-ribosylating bacterial toxins. It is secreted by toxic strains of the gram-positive bacillus Corynebacterium diphtheriae carrying a lysogenic bacteriophage, which contain the toxin encoding gene (Freeman, 1951).

Our purified DT is used in immunoassay manufacturing, but is also widely used in cell biology applications for depletion of DT-receptor expressing cells in transgenic mouse models. Every batch of our DT is activity tested in a cellular depletion assay.

Corynebacterium diphtheriae Antibodies

Corynebacterium diphtheriae antibodies supplied by The Native Antigen Company recognise Diphtheria toxin. Corynebacterium diphtheriae antibodies are suitable for immunoassay research and development.

We offer two antibodies, one being specific for the A chain of the toxin. These antibodies can be used as a pair in immunoassay design.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

A silver-lining from Zika virus?

Zika virus (ZIKV) is an enveloped single stranded RNA virus. It is a member of the Flavivirus genus of the family Flaviviridae, which is transmitted to humans primarily through the bite of the Aedes aegypti mosquito. In 2015, a major outbreak of Zika virus was...

Congenital CMV – a problem ignored?

Congenital CMV infection – a serious problem that receives little attention Cytomegalovirus (CMV) is a human specific double stranded DNA virus, belonging to the Herpesviridae family. CMV is ubiquitous and CMV infection is globally widespread. The virus can be...

New Nipah Virus antigens now available from The Native Antigen Company

Infection with Nipah Virus (NiV) was first recognised in Malaysia 1998/1999, where a major outbreak occurred in pigs and humans. NiV infection is now endemic in South Asia and several outbreaks of NiV infection have been reported in India and Bangladesh. Currently an...

Get in Touch With Us

The Native Antigen Company sometimes likes to send exclusive information and offers to our customers, please let us know if you are happy to receive these

5 + 5 =

Customer Feedback